6,035 Shares in IQVIA Holdings Inc. $IQV Bought by Redwood Investment Management LLC

Redwood Investment Management LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 6,035 shares of the medical research company’s stock, valued at approximately $1,166,000.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC boosted its position in IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in IQVIA during the 2nd quarter valued at approximately $514,000. First Trust Advisors LP grew its holdings in shares of IQVIA by 14.8% during the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after acquiring an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC raised its position in shares of IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,913 shares of company stock valued at $3,098,793 in the last quarter. 1.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IQV shares. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Royal Bank Of Canada boosted their target price on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Robert W. Baird upped their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Trading Up 0.8%

IQVIA stock opened at $261.57 on Thursday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The business’s fifty day simple moving average is $218.41 and its two-hundred day simple moving average is $188.59. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $262.51. The company has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a stock repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.